Research progress on reversal of drug resistance to Sorafenib in primary liver cancer
10.3760/cma.j.cn115396-20221223-00434
- VernacularTitle:索拉非尼治疗肝细胞肝癌耐药的逆转机制研究进展
- Author:
Fangyuan KUANG
1
;
Chuxiao SHAO
;
Fengfeng CHEN
;
Chaoyong TU
Author Information
1. 绍兴文理学院医学院，绍兴 312000
- Keywords:
Liver neoplasms;
Carcinoma, hepatocellular;
Reverse transcription;
Sorafenib;
Drug resistance
- From:
International Journal of Surgery
2023;50(4):279-284
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is a malignant tumor with high incidence rate and mortality worldwide. However, most patients are not suitable for radical treatment at the time of first diagnosis. As one of the important schemes for the treatment of HCC, one of the most representative drug is Sorafenib, which has certain survival benefits for HCC patients at different stages. However, the drug resistance of HCC to Sorafenib greatly limits its efficacy. So far, people have found that some natural substances, experimental agents and biological macromolecules can reverse the drug resistance of HCC to Sorafenib through tumor cell microenvironment, metabolism and other mechanisms. This article will summarize the above substances and their mechanism in order to provide research ideas for the improvement of Sorafenib′s treatment program.
